$CRNX News
Last published 1w ago
- 1w agoCRNXVertex Pharmaceuticals Third Quarter 2026 Earnings Call - CRINETICS PHARMACEUTICALS INCEarnings Call TranscriptsGood day and welcome to the Vertex Pharmaceuticals 3rd Quarter 2026 Earnings Call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star ke
- 1w agoCRNXVERTEX PHARMACEUTICALS THIRD QUARTER 2026 EARNINGS CALL - CRINETICS PHARMACEUTICALS INCEarnings Call TranscriptsGood day and welcome to the Vertex Pharmaceuticals 3rd Quarter 2026 Earnings Call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star ke
- 2w agoCRNXVERTEX INVESTOR EVENT AT THE AMERICAN SOCIETY OF NEPHROLOGY KIDNEY WEEK 2026 - CRINETICS PHARMACEUTICALS INCEarnings Call TranscriptsWe're going to get started. Thank you very much to everyone here in the room for finding us, despite locked doors and escalators and challenging room locations. We really appreciate it. Obviously, a very, very exciting A
- 2w agoCRNXVertex Investor Event at the American Society of Nephrology Kidney Week 2026 - CRINETICS PHARMACEUTICALS INCEarnings Call TranscriptsWe're going to get started. Thank you very much to everyone here in the room for finding us, despite locked doors and escalators and challenging room locations. We really appreciate it. Obviously, a very, very exciting A
- 1mo agoCRNXMorgan Stanley 24th Annual Global Healthcare Conference - CRINETICS PHARMACEUTICALS INCEarnings Call TranscriptsGreat. Good morning, everybody. I'm Terrence Flynn, Morgan Stanley's U.S. Biopharma Analyst. Pleased to be kicking off our 24th Annual Healthcare Conference here in New York City. For important disclosures, please see th
- 2mo agoCRNXWells Fargo 21st Annual Healthcare Conference - CRINETICS PHARMACEUTICALS INCEarnings Call TranscriptsAwesome. Last session of the day. Thank you very much for all for joining us today. My name is Mohit Bansal. I'm one of the biotech and pharma analysts here at Wells Fargo. And I have the Vertex IR team with us. Susie Li
- 2mo agoVRTXCRNXVertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership TeamBusiness WireCrinetics acquisition completed September 1, 2026 Charles Wagner, EVP, Chief Operating and Financial Officer to take on expanded COO role overseeing integration of Crinetics, effective immediately As part of a
- 3mo agoCRNXSECOND QUARTER 2026 EARNINGS CALL - CRINETICS PHARMACEUTICALS INCEarnings Call TranscriptsGood day and welcome to the Vertex Pharmaceuticals second quarter 2026 earnings call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star
- 3mo agoCRNXVRTXCrinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireAnnounced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired PALSONIFY® (Paltusotine) Net Product
- 4mo agoCRNXVertex Pharmaceuticals Acquisition of Crinetics Pharmaceuticals Conference Call - CRINETICS PHARMACEUTICALS INCEarnings Call TranscriptsGood day and welcome to the Vertex Pharmaceuticals conference call to announce the acquisition of Krenetics Pharmaceutical. All participants will be in a listen-only mode. Should you need assistance, please signal a conf
- 4mo agoVRTXCRNXVertex to Acquire Crinetics PharmaceuticalsBusiness Wire- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only,
- 4mo agoCRNXCrinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026GlobeNewswireSAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026 after the market closes.
- 5mo agoCRNXCrinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026GlobeNewswireData show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH New results from the Phase
- 5mo agoCRNXCrinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly ControlGlobeNewswireData from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms Treatment also resulted in stable or reduced pituitary
- 5mo agoCRNXCrinetics and Leading Patient Groups Launch 'Everyday Advocacy' Initiative to Empower People Across Endocrine Disease CommunitiesGlobeNewswireEveryday Advocacy provides people living with endocrine and endocrine-related conditions with education, support, and tools to facilitate more impactful healthcare team interactions Steering committee of five leading
- 5mo agoCRNXCrinetics' Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six PresentationsGlobeNewswireOral presentation features open label extension PALSONIFY™ (paltusotine) data, reinforcing its best-in-class potential in acromegaly following recent U.S. and E.U. approvals Two oral presentations of novel,
- 5mo agoCRNXCrinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026GlobeNewswireSAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 2-4,
- 6mo agoCRNXCrinetics Pharmaceuticals First Quarter 2026 Financial Results - Crinetics PharmaceuticalsEarnings Call TranscriptsHello, everyone. Thank you for joining us and welcome to the Krenetics Pharmaceuticals First Quarter 2026 Financial Results. After today's prepared remarks, we will host a question and answer session. If you would like t
- 6mo agoCRNXCrinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswirePALSONIFY™ (Paltusotine) Net Product Revenue of $10.3 Million for First-Quarter 2026, with 232 Enrollment Forms in the First Quarter Management Hosting Conference Call at 4:30 p.m. ET Today
- 6mo agoCRNXCrinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in AdultsGlobeNewswirePALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medical naïve and
- 7mo agoCRNXNeutrolis Appoints Caren Deardorf as Chief Business & Strategy OfficerGlobeNewswireMs. Deardorf is an experienced biopharma leader who will lead business development and corporate and commercial strategy as Neutrolis advances NTR-1011 into autoimmune diseases following positive Phase 1a results
- 7mo agoCRNXCrinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026GlobeNewswireSAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026 after the market closes.
- 7mo agoCRNXCrinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in AcromegalyGlobeNewswireSAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced the submission of a Marketing Authorization Application (MAA) to Brazil's National Health Surveillance Agency
- 8mo agoCRNXCrinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswirePALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Operationally Seamless Phase 2/3 Study of Atumelnant for the
- 9mo agoCRNXCrinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in MarchGlobeNewswireSAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that company management will participate in the following two upcoming investor conferences: TD Cowen 46th
- 9mo agoCRNXCrinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026GlobeNewswireSAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after
- 9mo agoCRNXCrinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)GlobeNewswireSAN DIEGO, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that the first patient has been dosed in the BALANCE-CAH Phase 2/3 trial evaluating investigational candidate
- 10mo agoCRNXCrinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that on January 10, 2026, the Compensation Committee of the Board of Directors granted non-qualified stock
- 10mo agoCRNXCrinetics Pharmaceuticals Announces Pricing of Public Offering of Common StockGlobeNewswireSAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) ("Crinetics"), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for
- 10mo agoCRNXCrinetics Pharmaceuticals Announces Proposed Public Offering of Common StockGlobeNewswireSAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) ("Crinetics"), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for
- 10mo agoCRNXCrinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal HyperplasiaGlobeNewswireStrong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Atumelnant (80 mg)
- 10mo agoCRNXCrinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal HyperplasiaGlobeNewswireSAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET to provide
- 10mo agoGTBPADCTSTROCRNX+1Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma PipelinesPR NewswireEquity Insider News Commentary – The oncology sector's pivot toward platform-based precision therapies has signaled smart money abandoning...
- 10mo agoCRNXCrinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 44th
- 11mo agoCRNXCrinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)GlobeNewswireSAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that the first patient has been dosed in the CALM-CAH Phase 3 trial evaluating investigational candidate
- 11mo agoCRNXCrinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO , Dec. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that on December 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock
- 11mo agoCRNXCrinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing TumorsGlobeNewswireSAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic or
- 11mo agoCRNXCrinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid SyndromeGlobeNewswireCAREFNDR underscores the potential clinical value of paltusotine beyond acromegaly, and demonstrates progress in Crinetics' commitment to addressing unmet needs in the neuroendocrine tumor community SAN DIEGO, Nov.
- 1y agoCRNXCrinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that on November 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock
- 1y agoCRNXCrinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswirePALSONIFY™ (Paltusotine) Launched in the U.S. with Encouraging Early Feedback from Patients and Physicians, and Positive Reimbursement Trends Reiterates Cash Burn of $340-370M and Cash Runway into
- 1y agoCRNXCrinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual MeetingGlobeNewswireSAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced three abstracts from its clinical development programs will be presented at the upcoming North American
- 1y agoCRNXCrinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that on October 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock
- 1y agoCRNXCrinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025GlobeNewswireSAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes.
- 1y agoCRNXPALSONIFY FDA APPROVAL CALL - CRINETICS PHARMACEUTICALS INCEarnings Call TranscriptsWelcome to the Krenetics Pharmaceuticals Personify FDA Approval Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a question-and-answer sessi
- 1y agoCRNXCrinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with AcromegalyGlobeNewswireNovel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly
- 1y agoCRNXCrinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that on September 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock
- 1y agoCRNXCrinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)GlobeNewswireSAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for atumelnant, a novel,
- 1y agoCRNXCrinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that on August 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock
- 1y agoCRNXCrinetics Pharmaceuticals, Inc. (CRNX) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoCRNXCrinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireRegulatory Interactions and Commercial, Medical and Corporate Preparations On-Track for PALSONIFY™ (paltusotine) New Drug Application with September 25, 2025 PDUFA Date Continued Progress on the